Quantitative assessment of the expanding complementarity between public and commercial databases of bioactive compounds by Southan, Christopher et al.
Page 1 of 17
(page number not for citation purposes)
Journal of Cheminformatics
Open Access Research article
Quantitative assessment of the expanding complementarity 
between public and commercial databases of bioactive compounds
Christopher Southan1,2, Péter Várkonyi3 and Sorel Muresan*3
Address: 1ChrisDS Consulting, S-42166, Göteborg, Sweden, 2EMBL-European Bioinformatics Institute, Wellcome Trust Genome Campus, 
Hinxton, Cambridge, CB10 1SD, UK and 3DECS Global Compound Sciences, Computational Chemistry, AstraZeneca R&D Mölndal, S-43183 
Mölndal, Sweden
Email: Christopher Southan - cdsouthan@hotmail.com; Péter Várkonyi - peter.varkonyi@astrazeneca.com; 
Sorel Muresan* - sorel.muresan@astrazeneca.com
* Corresponding author    
Abstract
Background: Since 2004 public cheminformatic databases and their collective functionality for
exploring relationships between compounds, protein sequences, literature and assay data have
advanced dramatically. In parallel, commercial sources that extract and curate such relationships
from journals and patents have also been expanding. This work updates a previous comparative
study of databases chosen because of their bioactive content, availability of downloads and facility
to select informative subsets.
Results: Where they could be calculated, extracted compounds-per-journal article were in the
range of 12 to 19 but compound-per-protein counts increased with document numbers. Chemical
structure filtration to facilitate standardised comparisons typically reduced source counts by
between 5% and 30%. The pair-wise overlaps between 23 databases and subsets were determined,
as well as changes between 2006 and 2008. While all compound sets have increased, PubChem has
doubled to 14.2 million. The 2008 comparison matrix shows not only overlap but also unique
content across all sources. Many of the detailed differences could be attributed to individual
strategies for data selection and extraction. While there was a big increase in patent-derived
structures entering PubChem since 2006, GVKBIO contains over 0.8 million unique structures
from this source. Venn diagrams showed extensive overlap between compounds extracted by
independent expert curation from journals by GVKBIO, WOMBAT (both commercial) and
BindingDB (public) but each included unique content. In contrast, the approved drug collections
from GVKBIO, MDDR (commercial) and DrugBank (public) showed surprisingly low overlap.
Aggregating all commercial sources established that while 1 million compounds overlapped with
PubChem 1.2 million did not.
Conclusion: On the basis of chemical structure content per se public sources have covered an
increasing proportion of commercial databases over the last two years. However, commercial
products included in this study provide links between compounds and information from patents
and journals at a larger scale than current public efforts. They also continue to capture a significant
proportion of unique content. Our results thus demonstrate not only an encouraging overall
expansion of data-supported bioactive chemical space but also that both commercial and public
sources are complementary for its exploration.
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Background
Since the arrival of ChEBI and PubChem in 2004 the
development of public domain web-based chemistry
databases can justifiably be termed a "big bang" [1-3].
Within the space of five years, the Chemical Structure
Lookup Service now claims 46 million unique structures,
followed by ChemSpider [4] and PubChem [5], each with
collections of 20 million compounds, eMolecules [6] with
10 million and ZINC [7] with 8.5 million. While these are
major enabling resources for those working at the inter-
face between chemistry and biology, their content is pre-
dominantly aggregated from commercial chemical
suppliers. Because only a minority of these compounds
can be linked to bioactivity data this can be termed the
vendor dilution effect. PubChem is an exception in that it
is not only an open chemical information repository but
also has a crucial focus on linking compounds to the
many types of biological information within the National
Center for Biotechnology Information (NCBI), including
an increasing amount of public assay data.
The problem of vendor dilution is addressed by special-
ised databases, both public and commercial, that focus on
smaller compound sets that have direct links to docu-
mented bioactivity i.e. that specific effects of these com-
pounds in biological systems, ranging from biochemical
assays to whole organism studies, have been measured or
recorded. For in vitro data they can thus include specific
links between compounds and the proteins whose activi-
ties they modulate. These can be classified as compound-
to-assay-to-protein relationships if they are explicitly sup-
ported by data within documents. Typically, a journal
paper or patent document "D" describes a biochemical
assay "A" with a quantitative result "R", for example, an
IC50 for compound "C" that define it as an inhibitor of
protein "P". The relationship between these five entities of
document, assay description, assay result, compound
structure and protein identifier (D-A-R-C-P) can be man-
ually extracted by expert curators and organised in a rela-
tional format, thereby converting unstructured to
structured information. The resultant databases are typi-
cally referred to as chemogenomic or large-scale structure-
activity relationship (SAR) databases.
Three databases in this study, GVKBIO, WOMBAT (com-
mercial) and BindingDB (public), include curated links of
this general type; although there are differences in exactly
how each of them is structured and populated. PubChem
also contains relationships of this type but these are gen-
erally curated by third parties. One example is the deposi-
tions from Nature Chemical Biology whereby the combined
efforts of authors and publishers provide (for subscribers)
reciprocal links to compounds where their activity data is
specified in the paper. PubChem BioAssays also contains
relationships of the A-R-C-P type where assays and their
results (A-R) are web-linked rather than document-linked.
Interesting exceptions are the 20 assays in PubChem sub-
mitted from BindingDB where the data have been
extracted from publications.
Databases compared in this work incorporate other types
of bioactivity relationships that cannot be detailed here
but four important examples should be mentioned. The
first is that BindingDB, as inferred from the name,
includes directly measured or transformed affinity data
i.e. where C-P becomes a "binds-to" relationship. The sec-
ond example is compounds extracted from the Protein
Data Bank (PDB) i.e. where C-P becomes an "is-a-ligand-
of" relationship. These are not only captured in PubChem
but also selectively in BindingDB and DrugBank for drugs
and drug-like compounds. The third example is what
could be called bibliographic or co-citation mapping. This
can be represented as D-R-C where the document, D, con-
tains information describing some qualitative in vivo
activity of the compound, e.g. from an animal study or a
clinical trial, but no quantitative parameters (A-R) can be
extracted. Examples would include the compound names
mapped to a drug profile in DrugBank and the compound
name-to-MeSH links in PubChem. The fourth is where
mapping can link the compound structure to quantitative
biological effects in vivo, e.g. pharmacological effects, met-
abolic profiling, or therapeutic efficacy. In cases where the
mechanism of action is unknown, these can become com-
pound-centric relationships (D-A-R-C) if the data do not
support a direct protein link. The power of data mining
across different types of relationships that intersect at the
same or similar chemical structures is clear. For example,
it can support causality for the biological effects of a par-
ticular compound where the SAR and therapeutic mecha-
nism of action in a clinical setting, as well as its efficacy in
an animal disease model, can be attributed to specific
inhibition of the enzyme target in vitro, a binding con-
stant, a PDB structure and linked to its conversion to
defined metabolites.
Data extracted into commercial databases in this study are
predominantly generated in a pharmaceutical R&D set-
ting. While those databases that map approved drugs to
their primary targets can justifiably be designated target-
centric it is necessary to be circumspect about such a clas-
sification because the protein mappings may infer other
mechanistic relationships. The first of these would be
non-target compound interactions not directly involved
in the therapeutic mechanism of action, such as albumin
binding or metabolic turnover by P450s. The second
could be termed anti-target effects, such as hERG binding.
The third type, commonly referred to as off-target interac-
tions (or polypharmacology if this is a designed property),
are derived from compound specificities recorded from
cross-screening results. An example used in this work isJournal of Cheminformatics 2009, 1:10 http://www.jcheminf.com/content/1/1/10
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the extraction of published protease inhibitors for BACE1.
While these documents are directed towards the discovery
of therapeutic candidates for Alzheimer's disease, they
often include inhibition data against the paralogue
BACE2 even thought this is not currently considered a
drug target.
There are number of recent publications describing the
proliferation of public and commercial cheminformatic
resources [8-10]. However, the quantitative comparison
of content has so far been limited to two recent studies
suggesting both sectors were offering unique content and
functionality for bioactive chemistry [1,11]. This work
describes an update on the first of these two studies that
shows significant changes in two years. We have added
new sources, collated information on compound-to-pro-
tein mappings and calculated compounds-per-document.
Database descriptions and processing
The criteria by which we selected databases for inclusion
in this study are outlined below:
1) They include curated compound-to-activity-to-pro-
tein mappings and/or some other focus on bioactivity
data.
2) They have been continually updated.
3) They have an established utility for drug discovery
within AstraZeneca.
4) We were familiar with their data structures, content
and sources.
5) For public databases we were able to download
their entire compound content, either directly or via
PubChem.
6) For commercial databases subscribed to by Astra-
Zeneca we had complete internal access to their com-
pound content (online-only sources were therefore
excluded).
7) Their formats allowed file conversions for structure
filtration.
8) The public databases had reciprocal links to
PubChem and could therefore be selected as a submit-
ting source within Entrez.
9) None of the commercial products included any
proprietary information i.e. all structures and associ-
ated data were extracted from published documents.
This study includes some changes from the 19 databases
and subsets used previously [1]. Two commercial data-
bases were dropped because they had not been updated
internally. One public drug set was also omitted because
it had not been updated. Three new databases were added,
a new Clinical Candidate product from GVKBIO (com-
mercial) as well as ChEBI and BindingDB (public)
because they had significantly increased their content and
functionality since our previous study. The BioAssay
actives and PDB ligand subsets were changed as described
below.
This section includes a brief summary of the databases
and subsets. We have included self-reported statistics of
their content from September 2008 or by selecting them
as a source in PubChem to obtain a compound count.
More detailed information is available from the source
references, database help facilities, and documentation
provided on the company websites.
PubChem
PubChem [5] is the NCBI public informatics backbone for
the NIH Molecular Libraries Initiative focused on small
molecules as systems biology probes and potential thera-
peutic agents. It consists of PubChem Compound
(unique structures), PubChem BioAssay (assay results),
and PubChem Substance (samples supplied by deposi-
tors). Because the identifiers are discussed in Results it is
necessary to distinguish between compounds and sub-
stances. A PubChem Substance Identifier (SID) represents
distinct chemical structures from each submitting source.
The PubChem Compound Identifier (CID) is essentially a
merge of those SIDs with an identical structure, i.e. a
reduced-redundancy representation. The statistics are 19.3
million compounds with 44.5 million links from 65 sub-
mitting sources i.e. on average each CID is a merge of 2.3
SIDs. Of the compounds, 784,039 have been tested in
1,190 assays. This connectivity is integrated into the Ent-
rez bioinformatic databases. The website includes com-
prehensive descriptions of data structures, content and
mining tools.
While the compound structures per se are all public it
should be noted that PubChem includes structures from
commercial databases but access to the out-linked infor-
mation requires a subscription. The largest submissions of
these are the 5.7 million substances from DiscoveryGate
[12] and 2.7 million from Thompson Pharma [13]. The
former is essentially a cross-matching process, i.e. out-
links are only added when they match pre-existing sub-
missions from another source, whereas the latter includes
de-novo deposition. Thus, the Thompson Pharma compo-
nent represents a "commercial-within-public" data
source. While this is of undoubted value for subscribers it
does have a confounding effect on our extrinsic compari-Journal of Cheminformatics 2009, 1:10 http://www.jcheminf.com/content/1/1/10
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sons with commercial databases because it was deposited
between the 2006 and 2008 snapshots. Therefore, some
of the increased overlap between PubChem and commer-
cial databases, recorded in the Results for 208, can be
ascribed to this. It should be pointed out that, while for
non-subscribers the value of PubChem structures without
informative out-links is limited, the 2.2 million entries
that have both DiscoveryGate and Thompson Pharma
SIDs do have some utility because of their implied bioac-
tivity.
DrugBank
The 2008 release of this public database includes, as spec-
ified on their website, 4,765 compounds divided into 71
nutraceuticals, 128 biotech (protein) drugs and 4,637
small molecule drugs. Of these, 1,485 are approved drugs,
3,243, experimental drugs, 188 illegal drugs and 64 with-
drawn drugs. Each DrugCard entry contains over 80
searchable data fields, with half being devoted to drug and
chemical data, and the other half to target-centred infor-
mation [14]. The SD files were downloaded directly from
the website as it is not yet possible to separately select the
approved or experimental sets from within PubChem.
BindingDB
This public database currently contains experimentally
determined enzyme kinetic data, measured or derived
binding affinities of protein-ligand complexes, and pro-
tein targets for small molecule ligands [15]. These data are
manually extracted from journals by curators but some
sets have been submitted by authors. This database has a
focus on proteins that are drug targets, candidate drug tar-
gets and/or in the Protein Data Bank. Identifiers for cura-
tion or submission sets, predominantly as PubMed IDs
from publications, are given on the website along with
September 2008 figures for 23,931 compounds and
45,363 Ki or IC50 data values. When selected from
PubChem, 23,021 CIDs were retrieved.
ChEBI
Chemical Entities of Biological Interest (ChEBI) is a pub-
lic database of endogenous and synthetic bioactive com-
pounds [16]. It also includes a chemical ontology
classification, whereby the relationships between molecu-
lar entities or classes of entities and their parents and/or
children are specified. It incorporates compounds speci-
fied in the Integrated relational Enzyme database (IntEnz)
of the European Bioinformatics Institute that contains the
recommended Nomenclature and Classification of
Enzyme-Catalysed Reactions [17]. It also incorporates
KEGG COMPOUND that is part of the LIGAND compos-
ite database of the Kyoto Encyclopaedia of Genes and
Genomes (KEGG) [18]. Release 48 of ChEBI specified
15,548 annotated entities on their website and the
PubChem selection provided 10,192 CIDs. While ChEBI
does not currently have direct bioactivity links to journal
articles, they have recently introduced automatically gen-
erated cross-reference where compound names are
matched with those extracted from patent documents via
the European Patent Office.
WOMBAT
WOrld of Molecular BioAcTivity (WOMBAT) is a com-
mercial database that includes specific links between com-
pounds and sequence identifiers for the proteins against
which these compounds have been shown to be active
[19]. In addition to the compound structures and activity
values, the species in which the tests were performed, an
activity classification of the compound as well as addi-
tional calculated properties are included. From the web-
site, WOMBAT 2008.1 contains 220,733 entries (192,529
unique SMILES) captured from papers published in
medicinal chemistry journals between 1975 and 2007.
Approximately 88% of the targets named in source docu-
ments have been assigned unambiguously to SwissProt
IDs.
GVKBIO
This study includes four separate commercial products
from GVKBIO, two of which have been merged into one
internal database in AstraZeneca [20]. This merge was
between the MedChem database of compounds extracted
from medicinal chemistry journals and the Target Inhibi-
tor Databases that are divided into nine sections, GPCRs,
proteases, kinases, ion-channels, NHRs, phosphatases,
transporters, phosphodiesterases and lipases. Com-
pounds in these nine target databases have been extracted
from both journals and patents. Compounds from the lat-
ter are selected from all exemplified claims with specified
activity data but capped at 500 for ranged activity values
or 200 examples for qualitative results. This merged data-
base is referred to as GVKBIO in the results and has been
described in outline [21]. The current content statistics
from direct queries are 3,344,068 compound links,
2,153,846 unique structures and 10,314,951 activity val-
ues extracted from patents and papers. The GVKBIO on-
line portal, GOSTAR, contains an equivalent merge and
includes the two products below plus additional sources.
The GVKBIO Drug Database (GVKBIO DD) contains data
on drugs approved by the US Food and Drug Administra-
tion (FDA) and other authorities. This data has been
extracted from pharmacological journals and other
sources. It includes protein target information, therapeu-
tic classification and pharmacokinetic parameters. The
Clinical Candidate Database (GVKBIO CCD) includes
compounds which are in various stages of drug develop-
ment with associated biological, pharmacological, target
identity and clinical pharmacokinetic information
extracted from journals covering clinical development ofJournal of Cheminformatics 2009, 1:10 http://www.jcheminf.com/content/1/1/10
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new drugs and patents. It includes FDA-approved com-
pounds, failed or discontinued clinical candidates, dis-
continued drugs, late-stage research compounds, those
reported in phase I, II and III trials as well as available
metabolite information.
MDDR
The MDL Drug Data Report (MDDR) is a commercial
database by Symyx/MDL that covers published docu-
ments, meeting reports and congress proceedings [22]. It
contains both the structures of compounds and their
derivatives. Compound-linked information includes bio-
activity, therapeutic classification, detailed patent infor-
mation, literature references, company names, compound
codes, generic names, trade names and development
phase. The 2008.1 release contained 185,844 com-
pounds.
DNP
The Dictionary of Natural Products (DNP) from Chap-
man & Hall/CRC is a commercial database of natural
products [23]. It arose as a daughter product of the Dic-
tionary of Organic Compounds (DOC) that has been in
book form for many years. It includes data on chemical,
physical and biological properties of compounds; system-
atic names, common names, CAS registry numbers, litera-
ture references; structure diagrams and connection tables.
Database Subsets
In addition to using complete compound collections we
selected subsets to provide insights into more specific
areas of bioactive coverage. The PubChem subsets were
extracted as PubChem CIDs and SMILES strings by using
the Entrez query and download facility. They were subse-
quently cross-matched to the entire set downloaded from
PubChem.
1. PubChem Prous: The Prous Drugs of the Future Jour-
nal publishes monographs with information on new
drug compounds in development. These were
retrieved by searching PubChem Compound with the
Entrez limit: "Prous Science Drugs of the Future" to
give 4,622 CIDs. While the out-link between the com-
pounds and the documents are explicit in PubChem,
this is not yet reciprocal i.e. there are neither links
from articles out to PubChem CIDs nor between com-
pounds and sequence identifiers of the targets that are,
in most cases, identifiable in the context of the docu-
ment.
2. PubChem PDB: While in our previous study we had
retrieved a specific set of small molecule ligands using
the data source "SMID", the update status of this set
was unclear. We therefore chose a larger set (PubChem
compound, Limits: Protein 3D Structure) that gave
12,756 records. This is an upper limit that includes
many entries that would not be classified as bound lig-
ands. By using the rule-of-five [24] chemical property
filters in PubChem this was reduced to a set of 5,706
compounds that should be predominantly drug-like
ligands.
3. PubChem actives: The PubChem BioAssay data-
base includes purified protein activity assays, cell-
based screens and other types of measurements. The
query used in our previous study, "active in any bio-
assay", was used to retrieve 11% of all compounds
screened at that time. However, it was subsequently
brought to our attention that this included not only
likely false positives from primary screens but also
compounds testing positive in various molecular
property assays such as fluorescence. This "active in
any bioassay" subset has now increased to over 20% of
all tested compounds. Because there are no options to
de-select molecular property assays the following fil-
ters were used to enrich for authentic bioactives within
the limitations imposed by standard Entrez queries.
The first was to select only those bioassays that had a
protein target, the second was those with specified
testing concentrations (typically for IC50s) and the
third was to restrict to confirmatory rather than pri-
mary screens. This produced 195 assays from 71
unique gene products. Retrieving actives from these
assays gave just over 21,000 compounds (this actually
selects those active in any assay but it was not possible
to select only from the 195 specific assays). The final
filter was to select compounds with an active concen-
tration of 1.0 μM or below. This combination pro-
duced 4,300 compounds that should be
predominantly the most potent actives from confirm-
atory dose-response biochemical assays against puri-
fied protein targets.
4. PubChem pharmacology: The MeSH index of
PubMed includes the category "pharmacology" for
drugs and other exogenously administered bioactive
compounds. It includes activators and inhibitors of
physiological or biochemical processes and other
pharmacological mechanisms of action. As MeSH-
defined compounds are linked into PubChem, the
Entrez query "pharmacological action" was used the
retrieve these. Surprisingly this compound subset had
decreased since our previous study from 12,038 to
10,785. It turns out that this category had undergone
a clean-up whereby spurious mappings caused by
naming errors in some submissions had been cor-
rected.
5. PubChem MLSMR: The new PubChem subset we
included was the NIH Molecular Libraries Small Mol-Journal of Cheminformatics 2009, 1:10 http://www.jcheminf.com/content/1/1/10
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ecule Repository (MLSMR) collection. This is used for
screening by the NIH Molecular Libraries Screening
Centre Network (MLSCN). The Entrez query in
PubChem Compounds for this set retrieved 300,585,
although screening results have so far been deposited
for only 232,839 of these. While some individual
assays use smaller subsets rather than the entire collec-
tion, these compounds have been used in 727 MLSCN
assays. The results generated contain increasing
amounts of cross-screening data as the assay collection
expands. In this case 80% of the compounds complied
with the rule-of-five filters [24]. This MLSMR subset is
therefore the conceptual equivalent of a pharmaceuti-
cal company screening collection.
6. GVKBIO journal: This subset of GVKBIO com-
pounds from the MedChem and Target databases was
selected by field code "journal" in the database.
7. GVKBIO patent: Subset of GVKBIO compounds
from the Target databases selected by field code "pat-
ent" in the database.
8. BACE1: From the GVKBIO database we extracted a
single example set of compounds that have been
tested for their activity against one specific molecular
target. We chose BACE1 for three reasons: 1) it has a
clearly delineated research phase as a validated drug
target for Alzheimer's disease [25], starting from 1999,
2) it has a paralogous gene family of only two mem-
bers, BACE1 and BACE2, and 3) with over 5,000 com-
pounds retrieved using the Entrez Gene ID 23621 for
human BACE1, it was close to the median compound-
to-human target numbers in the GVKBIO database
that are distributed between 1 and over 50,000. By
inspection of the documents linked to these com-
pound records it was established that, as expected,
these compounds had been tested in biochemical
assays for BACE1 substrate turnover and were predom-
inantly selective inhibitors of the protease although
some with low activity levels were included in the
screening result sets.
9. DrugBank approved: Approved small molecule
drugs were downloaded directly from the site as set of
SD files.
10. DrugBank experimental: Experimental drugs
including unapproved, withdrawn, illicit drugs,
enzyme inhibitors and potential toxins. These were
downloaded directly from the site as set of SD files.
11. MDDR launched: A subset from MDDR selected
by field code "launched" in the SD files.
Database Processing
For both the extraction of subsets from PubChem that
required multiple steps (e.g. active compounds and PDB
ligands) and the generation of complimentary data by
various combinations, the Entrez facility was used. Que-
ries were done at the compound level with particular
sources or subsets selected via the "Limits" tab. Following
the sequential selection of multiple compound sets the
appropriate Boolean combinations were selected via the
"History" tab and performing aggregations using OR as
well as determining overlaps with AND.
All commercial compounds were downloaded as SD file
format from their internal Oracle databases within Astra-
Zeneca. DrugBank was downloaded from its website as
SD files. All SD files were converted into SMILES strings.
Where indicated above, other public collections or subsets
were selected via the appropriate Entrez limit in PubChem
and downloaded directly as SMILES strings. After conver-
sion of all sources to SMILES, stereochemical information
was removed in order to avoid differences between repre-
sentational conventions and thereby allow a direct all-
against-all database comparison [26]. The non-isomeric
SMILES were further processed to determine the number
of unique structures in each database by the following
four-step filtration procedure:
1. Normalisation of each structure by removing small
fragments, such as counter ions, water, and neutralis-
ing remaining charges.
2. Derivation of a canonical tautomer using LEATHER-
FACE, an in-house molecular editor based on SMARTS
rules [27].
3. Generation of unique molecular hashcodes [28].
4. The retaining of unique structures by comparing the
molecular hashcodes.
The same molecular hashcodes were subsequently used to
identify the overlap between databases. All in-house
scripts and software used for this study are based on the
OpenEye toolkit [29].
Compound, Document and Protein Counts
The filtration process described above produced final
chemical structure counts for all sources and subsets.
These numbers are in Table 1 of the results section. Docu-
ment counts are the total number of discrete publications
from which the compound structures and protein identi-
fiers were extracted. For the GVKBIO products these were
generated from in-house queries restricted to patent num-
bers and PubMed IDs. In other cases document counts
were obtained from the web sources or suppliers informa-Journal of Cheminformatics 2009, 1:10 http://www.jcheminf.com/content/1/1/10
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tion. While we expect these predominantly to be in
PubMed the numbers for BindingDB and DNP are not
explicitly PubMed ID counts. Protein counts for the GVK-
BIO products were also generated by in-house queries of
distinct EntrezGene IDs with or without human in the
annotation field as an additional restriction. For WOM-
BAT the protein counts were supplied to us. In the case of
BindingDB and DrugBank we used the UniProtKB/Swiss-
Table 1: Database update numbers.
Dataset Oct 2006 Oct 2008 2008–2006 2008–2006
[%]
Filtration
2008
GVKBIO 1488288 2054151 565863 38% -8%
GVKBIO Journals 542858 658198 115340 21% -8%
GVKBIO patents 1034548 1484218 449670 43% -7%
GVKBIO DD 1933 3675 1742 90% -4%
GVKBIO CCD n/a 8864 n/a n/a -1%
GVKBIO BACE1 n/a 5228 n/a n/a -11%
GVKBIO BACE1 journals n/a 389 n/a n/a -6%
GVKBIO BACE1 patents n/a 4901 n/a n/a -11%
WOMBAT 128120 180856 52736 41% -18%
PubChem 7268193 14965539 7697346 106% -23%
PubChem Prous 3318 4652 1334 40% -2%
PubChem PDB 5626 5706 n/a n/a -8%
PubChem actives 35671 7472 n/a n/a -3%
PubChem pharmacol 6070 5311 n/a n/a -63%
PubChem MLSMR n/a 233284 n/a n/a -1%
PubChem BindingDB n/a 24203 n/a n/a -4%
PubChem ChEBI n/a 7428 n/a n/a -31%
DrugBank 3723 4545 822 22% -7%
DrugBank approved 1018 1341 323 32% -3%
DrugBank experimental 1737 2999 1262 73% -6%
DNP 131831 144383 12552 10% -26%
MDDR 159867 176600 16733 10% -4%
MDDR launched 1118 1435 317 28% -5%
This shows reductions in the compound figures after filtration in this work (2008). For those data sources that were also included in our previous 
publication the changes (2006 – 2008) are shown in absolute numbers and as a percentage. The reasons for the decrease in two of these are 
explained in the methods section. New sources that are not applicable to 2006/2008 changes are labelled n/a.Journal of Cheminformatics 2009, 1:10 http://www.jcheminf.com/content/1/1/10
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Prot database cross-reference for the protein counts rather
than figures from the websites as this enabled the addi-
tional restriction to human proteins. For the assay targets
linked to the PubChem actives and the PubChem PDB
compound set, the RefSeq identifiers were obtained but
species selects for these were not available via a standard
PubChem query.
Results and discussion
Post-Filtration number reductions and database increases
The growth rate of the databases and comparable subsets
we have used in this and our previous study are shown in
Table 1, together with the filtration results from 2008.
These latter figures generally show a significant reduction
compared to the self-reported compound counts from the
sources but it should be borne in mind that these may be
defined in different ways. Because of the inherent com-
plexity of chemical structure comparisons, the challenges
of standardising representations, and the difficulties of
quality control for large compound collections, none of
these sources are likely to claim their numbers as a stand-
ard of truth. For the same reasons we would not propose
our numbers as an absolute normalisation. Nevertheless,
this filtration process has proven robust and consistent in
our hands for standardising comparisons between com-
pound collections over a number of years. The use of sub-
sets provides internal controls and, in all cases, produced
exact number matches i.e. the subsets added up the parent
set. As evidence for the precision of these methods, some
of the results (e.g. the BACE1 set) show single-digit com-
pound overlaps that have been verified by manual inspec-
tion.
Establishing exactly what types of representational heter-
ogeneity have contributed to the filtration reductions in
Table 1 is not only outside the scope of this work but also
requires a level of process detail that not all vendors are
prepared to disclose. Nevertheless, because it is a) numer-
ically the largest source, b) has a level of technical trans-
parency where all internal links can be checked, and c) it
exemplifies important aspects of the general case, the
results from PubChem can be expanded briefly. As men-
tioned in Methods, on average, each CID is a merge of 2.3
SIDs. However, while it is crucial to preserve the individ-
ual SID representations, as supplied by the individual sub-
mitters, heterogeneity in these can feed through to a
multiplicity of CIDs. These can include mixtures, salts and
instances where different tautomers may, or may not, be
specified in different SIDs for the same compound. An
example would be the independent submissions of a drug
formulation as a mixture, each of the single components
and two different salt forms of just the active compound.
This would result in, according to the PubChem merging
rules, five CIDs that would have been filtered in this work
to just two structures.
While these factors have resulted in a 23% overall reduc-
tion in PubChem after filtration, it was surprising to note
in Table 1 that the Pharmacology subset showed the larg-
est reduction from any source of 63%. It turns out that this
subset has a high SID: CID ratio of 13:1. It therefore
includes different salts, protonation states and stereoi-
somers that have been mapped to the same MeSH chemi-
cal name. Consequently, this accumulation of SID
heterogeneity has spawned many CIDs linked with those
MeSH terms which have collapsed during our filtration
step to a much smaller number of unique parent struc-
tures.
All the independent sources in common between our
2006 and 2008 studies have expanded (the two instances
of subset contraction are explained in Methods). The larg-
est increase was in PubChem that effectively doubled in
size. The submission of 17.2 million substances from
ChemSpider at the end of 2007 that merged into 16.7 mil-
lion CIDs was clearly a major contribution, although the
absolute increase in CIDs from this source was only 6.2
million. The next largest increase at 73% was the Drug-
Bank experimental subset that underwent a release update
at the beginning of 2008. The remaining growth rates, in
the range of 10% to 30%, are more modest but these par-
ticular sources are based on manual document curation,
rather than bulk submissions. It is interesting to note that
the three sources of approved drugs, DrugBank approved,
MDDR launched and the GVKBIO Drug Database, show
similar growth rates in the region of 30%. The absolute
increases of over 300 seem high since the recent annual
FDA approval rates have only been in the 25–30 range,
suggesting these sources have processed a backlog over
this period [30].
Compounds-per-protein and compounds-per-document 
counts
While there are caveats associated with quantifying and
comparing these from different databases, Table 2 shows
the numbers obtained for selected parameters that could
be calculated. It is noticeable that, while the numbers of
compounds-per-journal article are comparable, the com-
pounds-per-protein show a trend in order of increasing
numbers of documents. This is explicable because the
same protein identifier would occur in many documents,
particularly for popular targets, and therefore the rate of
inclusion of unique protein identifiers would not be
directly proportional to the number of documents
extracted. Conversely, authors predominantly publish
new chemical structures tested against previously estab-
lished targets so the numbers of these would accumulate
as more papers were extracted. For the GVKBIO DD and
CCD the ratios are essential reversed i.e. large numbers of
documents are linked to a smaller number of compounds
and targets This many-to-one relationship is the expectedJournal of Cheminformatics 2009, 1:10 http://www.jcheminf.com/content/1/1/10
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consequence of extracting the numerous publications that
constitute the data corpus accrued over many years for
established primary targets, launched drugs and late-stage
candidates. For MDDR the compounds-per-document
(patents and papers in this case) lies between the two
extremes.
The noticeable differences between patent and journal
extractions in Table 2 are that the later produce fewer
compounds but more sequence identifiers. The fact the
exemplified compounds in patents outnumber those in
journal papers is unsurprising and this would be even
higher if it were not for the fact that GVKBIO cap the
examples extracted from patents with qualitative biologi-
cal data. The reason patents produce less human sequence
identifiers is that smaller target classes, outside the "big-
nine" listed in Methods, are not prioritised for extraction.
The reasons for less total sequence identifiers in patents
are not only the target class restriction but also because
activity data against non-human proteins is more com-
monly included in journal articles than patents.
Because DrugBank and BindingDB both have cross-refer-
ences in UniProtKB/Swiss-Prot the Sequence Retrieval
Service (SRS) can be used to ascertain proteins common
to both databases [31]. This gives the result of 39, of
which 35 are human. However, comparing these two
databases also illustrates some of the caveats. BindingDB
declare their total sequences mapped to compounds at
515. While there may be additional complications related
to accession numbers one of the reasons for an apparent
under-count when mapping to Swiss-Prot IDs is the cap-
ture of data for the many single amino acid protein vari-
ants used in binding studies that have the same Swiss-Prot
ID. Conversely, the number of primary targets for the
compounds in DrugBank is a significant over-count for
reasons explained in the publication [14]. In the context
of protein identifiers within databases the important util-
ity of being able to perform BLAST searches against the
actual sequences (and link back to compound data) is cur-
rently limited to DrugBank, BindindDB and the protein
targets in PubChem BioAssays.
The results in Table 2 can be viewed in the context of
established and predicted druggable genes. The lower
limit can be defined as the 207 human primary protein
targets of approved small-molecule drugs and 41 for path-
ogens [32]. The upper limit, extrapolated from this
Table 2: Compounds-per-protein and per-document.
Database or subset Document
count
Protein ID type Total
proteins
Human
proteins
Cpds-per-protein Cpds-per-document
GVKBIO 87747 Entrez Gene 3292 1468 604 22
GVKBIO journals 51810 Entrez Gene 2660 1146 239 12
GVKBIO patents 35937 Entrez Gene 1765 952 815 40
GVKBIO DD 26825 Entrez Gene 733 339 5 0.14
GVKBIO CCD 27286 Entrez Gene 1224 610 7 0.32
WOMBAT 10205 Swiss-Prot 1979 1095 91 18
DrugBank n/a Swiss-Prot 1625 1356 3 n/a
PubChem actives n/a RefSeq 72 n/a 104 n/a
PubChem PDB n/a RefSeq 818 n/a 14 n/a
BindingDB 1142 Swiss-Prot 297 97 112 19
MDDR 137754 n/a n/a n/a n/a 1.4
DNP 7765 n/a n/a n/a n/a 18
Column three is the type of protein identifier used for the count of all species (column four) and human proteins (column five). In columns six and 
seven the filtered compound totals are taken from Additional file 1. The compound ratios are calculated with respect to total proteins and 
documents. For boxes labelled n/a the information was either not applicable or not available. For reference we have included a compounds-per-
protein calculation for the PubChem actives subset even though there are no document-protein links analogous to the other sources.Journal of Cheminformatics 2009, 1:10 http://www.jcheminf.com/content/1/1/10
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drugged set, has recently been estimated at 2,200 human
genes [33]. Other key numbers include the 836 human
targets with some kind of documented chemical modula-
tion starting point [34]. Last but not least, was the presci-
ent estimate that the human genome could include 600–
1,500 tractable and therapeutically effective targets [35]. It
is of interest to note that numbers from the GVKBIO Med
Chem and Target databases of 1,468 human protein-com-
pound links are already approaching this upper limit
although, as mentioned in the introduction, this number
includes a proportion of non-targets. The GVKBIO DD
human protein count slightly exceeds known primary
drug targets because they also include some protein iden-
tifiers from cross-screening data. The higher protein count
in GVKBIO CCD can be attributed to two causes. The first
is the inclusion of proteins that are not yet targeted by
approved drugs, i.e. new targets, and the second is also the
inclusion of cross-screening data.
The absence of figures in Table 2 for some databases in the
study needs clarification. ChEBI does include protein
names mapped to compounds in their curated ontology
(e.g. hydroxymethylglutaryl-CoA reductase inhibitor) but
these are currently limited in number. It also includes
automatically generated cross-references to a number of
external databases. This includes UniProtKB entries for all
protein names associated with that particular compound
but these are not curated links. Protein names from the lit-
erature and inferred metabolic interactions may be associ-
ated with structures in DNP but there is no formal
mapping of these relationships. Compounds in MDDR
have links to therapeutic or generic activities. While it is
possible to extrinsically cross-map many of these to spe-
cific protein identifiers, these are not curated links in the
current data structure [36].
The Comparison matrix
We should point out that some of our explanations out-
lined below for the patterns of overlaps and their shifts
from our previous publications are speculative. There are
two reasons for this. The first is that, within the constraints
of this work, it has only been possible to make a limited
number of additional comparisons and manual inspec-
tion of selected entries to try to establish the basis for dif-
ferences. The second reason is that, compared to the many
journal articles and presentation slide sets describing pub-
lic databases, detailed information as to how commercial
databases are populated is not always available. Notwith-
standing, we have acquired extensive knowledge about
their content, including feed-back from vendors. This
informs our judgment despite the paucity of citable docu-
mentation. We thus consider our inferences not only to be
an informative part of this work but also to be testable by
further analysis. The results, presented as Table Three in
Additional file 1, will be referred to as column numbers
but these intersect with the same row numbers in the
matrix.
Column 1 shows the GVKBIO database has increased
since 2006 to just over 2 million compounds and is the
commercial source with the highest unique content in this
study. For the subsets in columns 2 and 3 the patent: jour-
nal ratio is 2.28:1 with just under 6% of patent com-
pounds overlapping with those appearing in journals,
presumably subsequent to the patent publication,
although some could be non-proprietary bench-marking
compounds. To our knowledge, such an important meas-
urement has not been reported elsewhere, except in our
previous study where it was 10%. As to whether this
decrease really represents acceleration in patent chemical
structure output relative to journals is perhaps too early to
establish. In fact, the overall numbers of patent-specified
structures eventually appearing in journals is likely to be
higher than these figures for three reasons. The first two
have been already mentioned in the GVKBIO database
descriptions, namely the necessity to cap compound
structure extractions from large applications and limit the
target classes covered by selected patent documents. The
third reason is that not all journals that might include
some compound bioactivity data from pharmaceutical
R&D are extracted.
In column 4 it can be see that, only 38% of the drug com-
pounds from GVKBIO DD are represented in patents but
75% overlap with GVKBIO journal compounds. The same
trends can be seen not only for the other drug collections
(columns 16 and 20) but also for the clinical candidate
compounds from GVKBIO CCD (column 6) i.e. that only
34% of the compounds are in patents but 62% overlap
with those from papers. Similar ratios can also be detected
in the Prous Drugs of the Future subset as an independent
development compound source i.e. with a 75% overlap
with GVKBIO papers but 37% for patents. While it would
seem unlikely for clinical candidates or approved drugs
not to have their structures claimed in patents the expla-
nations we propose for this have already been given
above, namely the extraction cap and target class restric-
tion for patents. The 89% overlap with GVKBIO CCD
establishes that the majority of clinical candidates are
being deposited into PubChem, possibly via other com-
mercial sources such as Thompson Pharma, but further
subset comparisons would be necessary to establish this.
Column 6 establishes that GVKBIO Journals covers 94%
of WOMBAT, just one percent more that in our 2006
study, showing the concordance between these independ-
ently curated sources remains high, even though both
have expanded significantly (Table 1). Column 7 shows
that PubChem covers the largest proportion of the com-
mercial databases in this study, with the exception ofJournal of Cheminformatics 2009, 1:10 http://www.jcheminf.com/content/1/1/10
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WOMBAT, where the 75% overlap with PubChem is
lower than the 94% with GVKBIO. From the comparison
between GVKBIO and PubChem the coverage of the
former by the latter has increased from 29% to 44%. Most
of this increase has come from GVKBIO Patents where
PubChem now overlaps with over 0.63 million com-
pounds, almost doubling from 2006. There are two likely
sources for this increase. The first is Thompson Pharma
that also includes patent-extracted compounds; the sec-
ond would be via ChemSpider from the SureChem online
patent database [37] that automatically converts names to
structures from patent documents. However, our results
show that the patent-derived coverage by GVKBIO not in
PubChem has risen from 0.79 million in 2006 to 0.85
million in 2008.
The PubChem Prous compounds in column 8 have the
highest overlap with GVKBIO at 79%, even though Drugs
of the Future is not currently a source journal. An explana-
tion is that compound-sequence links have been picked
up from the primary literature before appearing in the
Prous review articles. In this context, the 50% coverage by
MDDR seems low. The PDB ligand set in column 9 shows
the highest coverage of 50% in GVKBIO followed by 28%
in DrugBank. An unexpected result from the PubChem
actives in column 10 was that 32% are not in the MLSMR
screening collection. While there are certainly submis-
sions to PubChem BioAssay for protein targets run against
other screening collections it also turns out that, for some
of the confirmatory assays the chemical space around
selected primary hits has been expanded by the acquisi-
tion or synthesis of new analogues not in the original col-
lection. While they should eventually be added, there is a
time lag in this process.
In column 11 GVKBIO has the highest overlap with the
PubChem pharmacology subset at 81%. An explanation is
that many compounds whose activity in vitro is published
are also tested in vivo and therefore eventually indexed in
MeSH. In column 12 the MLSMR collection has little over-
lap with other sets which, doubtless, reflects the diversity
emphasis of the acquisition strategy [38]. However, the
overlaps also suggest the collection still has some way to
go in regard to the declared objectives of increasing the
content of known drugs and natural products because it
has only about 50% of the former (columns 4,16 and 20)
and less than 0.5% overlap with the latter (column 18). It
is also noteworthy that the GVKBIO overlap of just over
2% in the screening collection, rises to 19% in the selected
actives (column 12). This suggests an enrichment of com-
pounds with reported bioactivity, despite the fact that the
MLSCN pilot phase has tended to screen different protein
targets than those represented in the GVKBIO document
sources that are predominantly derived from pharmaceu-
tical R&D activities.
The results in column and row 13 include BindingDB for
the first time. GVKBIO journals cover 92% of its content.
The 8% difference could be in part due to experimental
thermodynamic binding data captured in BindingDB that
is not one of the assay data types typically extracted by
GVKBIO. Column 14 shows the coverage of ChEBI. While
GVKBIO shares the highest proportion of content at 44%
the low coverage of other databases point to unique con-
tent of enzyme intermediates and metabolites. While the
36% overlap shows some of these are in DNP the metab-
olite coverage is supported by a 56% overlap between
ChEBI and KEGG (from a comparison done within
PubChem). ChEBI also contains 25% of DrugBank.
Columns 15, 16 and 17 are the DrugBank total, approved
and experimental drugs respectively. The total exceeds the
number represented within PubChem by 175 because we
downloaded these directly from DrugBank. The 68%
overlap with GVKBIO is predominantly with journal con-
tent rather than patents. Of the approved drugs 86% are
in PubChem pharmacology but only 66% in GVKBIO pat-
ents. Overlaps between DrugBank and other drug sets are
reviewed below. Column 18 shows that the natural prod-
uct structures have a 56% overlap with PubChem and
12% with GVKBIO. The figures in column 18 suggest (but
would need a Venn-type analysis to confirm) that DNP is
the commercial source with the second highest unique
content in this study. Columns 19 and 20 show the split
between MDDR total and launched. The total shows 63%
overlap with PubChem and 45% with GVKBIO. The over-
laps for MDDR launched are detailed in a later section.
Columns 21 to 23 are the set of BACE1-linked com-
pounds retrieved from GVKBIO. The number from pat-
ents is 12.6 times that from journals, confirming the
importance of patents as a published source of com-
pounds directed against drug targets. WOMBAT and
BindingDB have extracted the same compounds from
journals, at 154 and 55 respectively. While these would be
expected to be research compounds for BACE1 inhibition
there are also matches in GVKBIO DD and GVKBIO CCD
(rows 4 and 5). Inspection of these individual compounds
revealed two explanations. One of the intersects with
GVKBIO CCD was PubChem CID 11537623. This is a
BACE1 inhibitor that, as a development candidate, had
been captured in GVKBIO CCD. One of the intersects with
GVKBIO DD was PubChem CID 5493444, the approved
Novartis rennin inhibitor Aliskiren. This is clearly a case of
cross-screening against the same target class. This also
turns out to be the same compound that is responsible for
the single match between the BACE1 set, DrugBank
approved and MDDR launched.Journal of Cheminformatics 2009, 1:10 http://www.jcheminf.com/content/1/1/10
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Venn-type results for selected databases and subsets
A limitation of the data in Additional file 1 is that truly
unique content needs to be defined in terms of a Venn-
type series of B+C+D-A, A+C+D-B and so on. This was per-
formed on three subsets with common themes and in two
of these cases we can make a comparison with equivalent
data from the previous study. As a consequence of our first
inclusion of BindingDB in this publication, the Venn dia-
gram in Figure 1 is able to show overlaps and unique con-
tent between three databases that operate a conceptually
similar curation model. The concordance of 177,435
between pairs is evidence for the impressive consistency of
expert chemical structure extraction from an overlapping
document corpus, in this case predominantly medicinal
chemistry papers, by three independent curation teams on
three different continents, India for GVKBIO, Romania for
WOMBAT and USA for BindingDB. Considering the doc-
ument ratio of approximately 50:9:1 the larger unique set
in GVKBIO journals is unsurprising. The non-overlaps in
the two smaller databases are likely to be due to differ-
ences in selectivity from journal coverage and/or in the
choice of compounds extracted from particular articles.
The diagram in Figure 2 also includes WOMBAT but com-
pares to GVKBIO and PubChem across an approximate 2-
year interval over which the three-way overlap has
increased. This defines a potentially high-value consensus
bioactive subset because these compounds not only show
concordance between independent sources but may also
link to additional information and/or screening data in
Compounds extracted from Journals Figure 1
Compounds extracted from Journals. A Venn diagram showing the content overlap and differences between the data-
bases or subsets that contain compound structures extracted from medicinal chemistry journals. The data source name and 
compound totals are given outside each of the three circles.Journal of Cheminformatics 2009, 1:10 http://www.jcheminf.com/content/1/1/10
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Comparison of GVKBIO, WOMBAT and PubChem Figure 2
Comparison of GVKBIO, WOMBAT and PubChem. A Venn diagram showing the content overlap and differences 
between GVKBIO, WOMBAT and PubChem. The older 2006 versions are shown in (A) and 2008 from this publication in (B). 
The data source name and compound totals are given outside each of the three circles.Journal of Cheminformatics 2009, 1:10 http://www.jcheminf.com/content/1/1/10
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the PubChem system. The second trend over the two years
is that while the number of compounds unique to GVK-
BIO is still over a million there has been a doubling in the
PubChem overlap due to the increase in patent-derived
compounds entering PubChem as shown in Additional
file 1.
Figure 3 shows the Venn diagram for the database and two
subsets that capture approved drugs, MDDR launched,
GVKBIO DD (both commercial) and DrugBank approved
(public), for this and the previous study. While the con-
cordance between these three sets has increased from 522
to 807 over two years, we would expect this three-way
overlap to be approximately 1,300, although the pair-wise
overlap is 1,623. One possibility is that extraction from
different sources is the cause of the representational differ-
ences. Further investigation to confirm this could be
important given the lack of an officially authenticated set
of standardised compound structures from the FDA and/
or other national approval bodies. Numbers have been
recently proposed as 1,323 from the FDA Orange Book
but without structures [39]. Drugs@FDA also has a listing
but structures are only represented as images on the
labels. Wikipedia has a useful unofficial collection with
name-to-PubChem and DrugBank structure mappings
but this is still being populated [40].
Public versus commercial totals
As an adjunct to the individual comparisons we investi-
gated overlaps for larger merges. By aggregating all the
commercial sources in our 2006 study we obtained
1,711,674 with a collapse rate (compounds-in-common)
of only 11%. Comparing this with 7,268,193 for
PubChem gave an overlap of 524,083. The equivalent
numbers for this 2008 study (there are some differences in
sources but these are numerically small) are 2,284,464 for
the commercial merge, also with an 11% collapse and
14,965,539 for PubChem. The two collections have
1,043,399 compounds in common. Thus 1,241,065 or
approximately 65% of the compounds in these commer-
cial collections are "outside" PubChem. The comparison
between 2006 and 2008 not only shows increased overlap
but also increased unique content in both sectors. This
expanding complementarity is even more substantial con-
sidering the nesting of the 2.7 million Thompson Pharma
commercial bioactive collection within PubChem that
occurred between the two snapshots.
While a substantial proportion of compounds outside
PubChem come from patents in GVKBIO they are none-
theless a rich source of bioactives. To put this in perspec-
tive an approximate maximum public bioactive count (i.e.
compounds that would link to a publication and/or assay
data within the system) was made by adding the following
PubChem queries; KEGG, Nature Chemical Biology, Drugs
of the Future, BindingDB, DrugBank, Protein 3D Structure,
ChEBI, Pharmacological Action, PubMed via MeSH,
PubMed and Active in any BioAssay. This produced
311,123 compounds, i.e. only 26% of the number outside
PubChem and even these will contain a proportion of
false positives from primary screens and molecular prop-
erty assays. What should also not be overlooked for the
exploration of bioactivity is the value of the negative data,
particularly to discern structure-activity relationships, for
those 637,022 compounds that have been tested but
found to be inactive in the current assay collection.
Conclusion
The expanded complementarity between public and com-
mercial databases established in this work is a testimony
to the vibrancy of the field. However, it does present users
with the challenge of selecting sources whose utility best
matches their technical and scientific objectives. There
are, of course, many criteria that can be used for compar-
ative evaluation. These include: coverage, data structure,
searching options, export facilities, interface navigability,
documentation, learning curve, update frequency, con-
tent quality, data mining features, connectivity with other
sources as well as price and contractual restrictions for
commercial products.
We suggest that such assessments inevitably remain
incomplete without the direct comparison of compound
content along the lines that we have reported. It should be
pointed out that the determination of unique content and
overlap both have high value. While the former can be
conceived as an advantage it is important to understand
the basis of this uniqueness before value can be ascribed.
For example, it could mean that compounds have been
extracted from some hitherto overlooked important
source or, on the other hand, could have been generated
as a consequence of heterogeneity and/or errors in struc-
tural representation. Two examples from this work high-
light the issue. The GVKBIO data structure has the facility
to select patent-only compounds. Consequently, our
analysis was able to show that a substantial part of their
unique content was derived from this source. While many
of these have matches within PubChem, the entries do
not currently include direct links to patents. In some cases
such links are available indirectly via subscription data-
bases. For DNP we were also able to show substantial
unique content. While this natural product subset may
have considerable value it is not clear which document
selection or compound extraction strategies have given
rise to this uniqueness.
A parsimonious interpretation of the overlap between
databases might consider this as redundancy among pub-
lic sources or "paying for the same stuff twice" in commer-
cial ones. However, this overlooks one of the mostJournal of Cheminformatics 2009, 1:10 http://www.jcheminf.com/content/1/1/10
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Comparison of drug databases Figure 3
Comparison of drug databases. A Venn diagram showing the content overlap and differences between GVKBIO DD, 
MDDR launched and DrugBank approved. The 2006 versions are shown in (A) and 2008 from this publication in (B). The data 
source name and compound totals are given outside each of the three circles.Journal of Cheminformatics 2009, 1:10 http://www.jcheminf.com/content/1/1/10
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important advances in contemporary informatics, namely
the ability to synergistically combine data mining results
between different sources that contain common entities,
although this is often not a trivial exercise because of dif-
ferences in data organisation and entity identifiers. In
addition to largely standardised compound representa-
tions (SD files, SMILES or InChIs) some of the data
sources described also contain common document
(PubMed IDs or patent numbers) and protein identifiers
(Swiss-Prot or Entrez Gene IDs) that can be extracted and
cross-mapped.
There are two other advantages to determining common
compound content. The first of these is extrinsic quality
control, i.e. shared identical compounds are probably cor-
rect (the GVKBIO/WOMBAT concordance described
above being a good example). The second is what could
be termed orthogonal added value where complementary
information can be combined for the same compounds
even just by following out-links to different connecting
databases. An example can be shown by querying
PubChem for the structures in common between ChEBI,
BindingDB and DrugBank. The resulting 133 compounds
not only have a rich set of links from the three sources but
also a fourth set within PubChem that includes BioAssay
data for 119 of them.
In addition to the representation of chemical structure we
suggest the curated links between compounds, proteins
and documents constitute a very high intrinsic value for
the databases that include them. Consequently, we have
compared these where possible in this study. Whilst
acknowledging the challenges of quantifying these rela-
tionships it is to be hoped that these kinds of metrics may
become more widespread and standardised in the future.
While our results document the increase in public bioac-
tives over the last two years, they also demonstrate the
parallel expansion of commercial sources. Given that the
latter are entirely derived from published documents or
other non-confidential sources, the persistence of unique-
ness shows the complementary scope of compound
extractions and relationships captured by these products.
However, the coverage pendulum will undergo a further
swing in the public direction when the ChEMBL database
comes on-line at the European Bioinformatics Institute
towards the end of 2009 [41,42]. The result of a commer-
cial-to-public transfer, this new source will include close
to half a million compounds linked to protein identifiers
and bioactivity information extracted from journal
papers.
These developments currently present users with the best
of both worlds. The academic sector and small companies
who might not be able to afford commercial products
have access to expanding resources, undreamt of even a
few years ago, to enable their research in all areas of bio-
active chemistry [9]. Even compound structures from pat-
ent documents, traditionally exclusively brokered by the
commercial sector, have recently become accessible not
only via the collaboration between Freepatentsonline
[43], SureChem [37] and ChemSpider [4] but now also
via ChEBI [14].
At the same time, companies or larger academic institu-
tions that can invest in commercial databases to support
drug discovery and/or chemical biology are likely to con-
tinue to do so, as long as vendors maintain content and
functionality that are complementary to public sources.
However, pharmaceutical companies in particular, are
faced with the competitive necessity of exploiting both
types of resource and integrating them efficiently. A good
example of this in practice is the AstraZeneca implemen-
tation of the merged GVKBIO MedChem and Target Class
products referred to in Methods. This currently includes
out-links to PubMed for the scientific literature, MicroPat-
ent [44] for patent documents, Entrez Gene for sequence
identifiers, and PubChem CIDs as well as ChemSpider
IDs for compound matches. Matches to AstraZeneca's
Compound Collection are linked to internal screening
data and some that do not match this collection but
match compounds from preferred suppliers will have
these links as well. This powerful combination not only
takes full advantage of the overlap between the GVKBIO
compounds and public sources but also the unique con-
tent quantified in this work.
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